150
Participants
Start Date
July 3, 2023
Primary Completion Date
April 30, 2030
Study Completion Date
April 30, 2030
Imlifidase administered in the 20-HMedIdeS-19 (PAES) study
Imlifidase is an immunoglobulin G (IgG)-degrading enzyme of Streptococcus pyogenes that is highly selective towards IgG. The cleavage of IgG generates one F(ab')2- and one homodimeric Fc-fragment and efficiently neutralizes Fc-mediated activities of IgG.
Best available treatment administered in the 20-HMedIdeS-19 (PAES) study
Normal transplantation routine Transplantation and pre- and post-transplantation therapies in accordance with the clinic's normal transplantation routine.
RECRUITING
Medizinische Universitaet Wien, Vienna
RECRUITING
Hospital Universitario 12 De Octubre, Madrid
RECRUITING
Azienda Ospedaliera di Padova, Padua
RECRUITING
Nephrology Clinic Vídeňská 1958/9, Prague
RECRUITING
Hospital Universitario del Vall d´Hebron, Barcelona
RECRUITING
Unidad de Trasplante Renal, Barcelona
RECRUITING
Uppsala University Hospital, Uppsala
Lead Sponsor
Hansa Biopharma AB
INDUSTRY